Lv11
40 积分 2024-10-20 加入
The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023
3小时前
求助中
Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer
1个月前
已完结
Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer
3个月前
已完结
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
3个月前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer
4个月前
已完结
Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV
4个月前
已关闭
Advances in antibody-drug conjugates for endometrial cancer
4个月前
已完结
Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial
4个月前
已完结
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
4个月前
已完结
皖公网安备34019202002308
